Share price blitzed, analysts in an uproar after lead PhIII drug implodes — and Biogen unveils a $2.5M raise for the CEO
At this stage, you have to give Biogen CEO Michel Vounatsos top marks for the worst timing in the industry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
